Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15344952 | 0.90 | CYP11B1 (0.55) | MMP12KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15341904 | 0.84 | ALDH1A1 (0.54) | MMP12KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12405077 | 0.82 | MAPT (0.58) | MMP12KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30648411 | 0.81 | MAPT (0.57) | MMP12KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15345045 | 0.80 | MMP12 (0.46) | MMP12KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL19188055 | 0.79 | MMP12 (0.77) | MMP12KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL279594 | 0.79 | MMP12 (1.00) | MMP12KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4267366 | 0.79 | MMP12 (0.70) | MMP12KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14423372 | 0.78 | KDM4E (0.53) | MMP12KDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14423371 | 0.78 | KDM4E (0.55) | MMP12KDM4ERAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MMP12 2156/4885KDM4E 4221/4885RAB9A 181/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MMP12 2156/4885KDM4E 4221/4885RAB9A 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.